PL82863B1 - - Google Patents
Download PDFInfo
- Publication number
- PL82863B1 PL82863B1 PL1971146572A PL14657271A PL82863B1 PL 82863 B1 PL82863 B1 PL 82863B1 PL 1971146572 A PL1971146572 A PL 1971146572A PL 14657271 A PL14657271 A PL 14657271A PL 82863 B1 PL82863 B1 PL 82863B1
- Authority
- PL
- Poland
- Prior art keywords
- transition metal
- formula
- ions
- oxime
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 16
- 150000002923 oximes Chemical class 0.000 claims description 8
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 6
- KYTWXIARANQMCA-PGYIPVOXSA-N (3r,4s,5s,6r,7r,9r,10z,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradec Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N\O)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-PGYIPVOXSA-N 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 150000002466 imines Chemical class 0.000 claims description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 claims description 2
- 150000003623 transition metal compounds Chemical class 0.000 claims 3
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims 1
- 229910001430 chromium ion Inorganic materials 0.000 claims 1
- 229910001456 vanadium ion Inorganic materials 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- XCLJRCAJSCMIND-JCTYMORFSA-N (9S)-erythromycyclamine Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)[C@@H](N)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XCLJRCAJSCMIND-JCTYMORFSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910000497 Amalgam Inorganic materials 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- ZOYWWAGVGBSJDL-UHFFFAOYSA-N D-desosamine Natural products CC1CC(N(C)C)C(O)C(O)O1 ZOYWWAGVGBSJDL-UHFFFAOYSA-N 0.000 description 1
- IDRYSCOQVVUBIJ-UHFFFAOYSA-N Erythromycin-B Natural products CC1C(OC2C(C(CC(C)O2)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(C)C(CC)OC(=O)C(C)C1OC1CC(C)(OC)C(O)C(C)O1 IDRYSCOQVVUBIJ-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229910021550 Vanadium Chloride Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- VTJCSBJRQLZNHE-CSMHCCOUSA-N desosamine Chemical group C[C@@H](O)C[C@H](N(C)C)[C@@H](O)C=O VTJCSBJRQLZNHE-CSMHCCOUSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- -1 erythromycin B oxime Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- RPESBQCJGHJMTK-UHFFFAOYSA-I pentachlorovanadium Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[V+5] RPESBQCJGHJMTK-UHFFFAOYSA-I 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- INCPMRSWRODNTN-UHFFFAOYSA-N trichloro-$l^{3}-chlorane Chemical compound ClCl(Cl)Cl INCPMRSWRODNTN-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1752970 | 1970-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL82863B1 true PL82863B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-10-31 |
Family
ID=10096769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971146572A PL82863B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1970-04-13 | 1971-03-01 |
Country Status (21)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0056291B1 (en) * | 1981-01-09 | 1986-01-08 | Pierrel S.p.A. | Novel semisynthetic macrolidic antibiotics, microbiological processes for their preparation and related microorganism, novel intermediate compounds for their preparation and related pharmaceutical compositions containing them |
| US4847242A (en) * | 1985-03-12 | 1989-07-11 | Beecham Group P.L.C. | 11-ether derivatives of erythromycins |
| ZA87591B (en) * | 1986-02-03 | 1988-09-28 | Lilly Co Eli | Novel derivatives of eryhromycylamine |
| US5110800A (en) * | 1986-02-18 | 1992-05-05 | Eli Lilly And Company | Derivatives of erythromycylamine |
| US5075289A (en) * | 1988-06-07 | 1991-12-24 | Abbott Laboratories | 9-r-azacyclic erythromycin antibiotics |
| CN106188187A (zh) * | 2016-07-31 | 2016-12-07 | 合肥远志医药科技开发有限公司 | 一种地红霉素工业化生产方法 |
-
1970
- 1970-12-31 GB GB1752970*[A patent/GB1341022A/en not_active Expired
-
1971
- 1971-02-08 ZA ZA710762A patent/ZA71762B/xx unknown
- 1971-02-09 IE IE145/71A patent/IE35378B1/xx unknown
- 1971-02-09 CA CA104,875A patent/CA952517A/en not_active Expired
- 1971-02-12 DE DE19712106616 patent/DE2106616A1/de active Pending
- 1971-02-18 BE BE763131A patent/BE763131A/xx unknown
- 1971-02-22 NL NL7102292A patent/NL7102292A/xx unknown
- 1971-02-24 CS CS711373A patent/CS190356B2/cs unknown
- 1971-02-24 IL IL7136286A patent/IL36286A/xx unknown
- 1971-02-25 SU SU7101627128A patent/SU584778A3/ru active
- 1971-02-26 YU YU485/71A patent/YU35774B/xx unknown
- 1971-02-26 AT AT169571A patent/AT306922B/de not_active IP Right Cessation
- 1971-02-26 CH CH286871A patent/CH526533A/fr not_active IP Right Cessation
- 1971-03-01 JP JP7110335A patent/JPS5343516B1/ja active Pending
- 1971-03-01 PL PL1971146572A patent/PL82863B1/pl unknown
- 1971-03-01 RO RO197166112A patent/RO58354A/ro unknown
- 1971-03-01 DK DK91871AA patent/DK130467B/da unknown
- 1971-03-01 FR FR7106912A patent/FR2086006B1/fr not_active Expired
- 1971-03-01 BR BR1247/71*[A patent/BR7101247D0/pt unknown
- 1971-03-15 SE SE7103305A patent/SE376003B/xx unknown
- 1971-03-17 US US00125400A patent/US3780019A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zee-Cheng et al. | Antineoplastic agents. Structure-activity relationship study of bis (substituted aminoalkylamino) anthraquinones | |
| EP0041355B1 (en) | Novel erythromycin compounds | |
| Lefemine et al. | Isolation and characterization mitiromycin and other antibiotics | |
| EP2966069B1 (en) | Preparation of 3-[(s)-7-bromo-2-(2-hydroxy-propylamino)-5-pyridin-2-yl-3h-1,4-benzodiazepin-3-yl]propionic acid methyl ester with a work-up method without ammonium containing solutions | |
| Drabowicz et al. | Organosulfur compounds. 30. Improved procedure for synthesis of chiral sulfoxides | |
| PL82863B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| Chandross | Bisgalvinoxyl, 1 a Stable Triplet | |
| Slawinski et al. | The structure of erythromycin A cyclic carbonate | |
| US7220855B2 (en) | Process for producing methylcobalamin | |
| EP0574195B1 (en) | Antitumoral 5,8-dihydrodiazaanthracenes | |
| DE2724597A1 (de) | Verfahren zur herstellung von kanamycin c und dessen desoxyderivaten, die so hergestellten derivate und mittel, die diese derivate enthalten | |
| US2803650A (en) | Neodihydrostreptomycin and acid addition salts | |
| EP0072351B1 (en) | Aminoglycoside derivatives, processes for their production, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticals | |
| THOMAS et al. | SPECTINOMYCIN MODIFICATION III. SPECTINOMYCIN ANALOGS WITH C-3'-BRANCHED CHAIN SUGARS | |
| Tsukayama et al. | Transition-metal binding site of bleomycin. Cobalt (III) bleomycin | |
| Ohno et al. | NAD (P)+-NAD (P) H models. 69. Mechanism of stereospecific (NET) hydride transfer controlled by electronic effect. | |
| EP1029867B1 (en) | Process for the preparation of organic azides | |
| KR790001433B1 (ko) | 에리스로 마이실아민 화합물의 제조방법 | |
| Drandarov et al. | Lithium and proton templated ω-polyazamacrolactamization, new general routes to macrocyclic polyamines | |
| Freifelder et al. | Hydrogenation in the Pyridine Series. II. Catalytic Reduction of 2-Monoalkyl-and 2-Dialkylaminopyridines | |
| Cevasco et al. | The E1cB mechanism in the alkaline hydrolysis of N, N-diethyl-P-(3, 5-dimethyl-4-hydroxyphenyl) phosphonamidic chloride | |
| NO157497B (no) | Fremgangsm te for dekarbonylering av et alkylformat | |
| Blum et al. | Cu2+-catalyzed peptide bond formation in the reaction of 5-deoxypyridoxal and α-phenyl-α-aminomalonic acid | |
| Maier et al. | Modification of spectinomycin 1. Synthesis of 4-aminospectinomycins | |
| JP3069824B2 (ja) | ２−クロロ−４−ニトロフェニル−α−Ｄ−マルトトリオシドの製造方法 |